The novel HMG-CoA reductase inhibitor, pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO)

Yakugaku Zasshi

Volumn 124, Issue 3, 2004, Pages 121-126

  Tokoro, Takashi ^a   Wang, Juyong ^a   Kitajima, Isao ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Nitric oxide (NO); Pitavastatin; Vascular endothelial cell

Indexed keywords

GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PITAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; ISOPRENOID PHOSPHATE; NITRIC OXIDE SYNTHASE; QUINOLINE DERIVATIVE;

ARTICLE; CELL GROWTH; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; STATISTICAL SIGNIFICANCE; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; CELL CULTURE; CELL DIVISION; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; METABOLISM; TIME; UMBILICAL VEIN;

CELL DIVISION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLYISOPRENYL PHOSPHATES; QUINOLINES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 2542432189     PISSN: 00316903     EISSN: None     Source Type: Journal    
DOI: 10.1248/yakushi.124.121     Document Type: Article

References (22)

1. Scandinavian Simvastatin Survival Study Group., Lancet, 344, 1383-1389 (1994).
2. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J., N. Engl. J. Med., 333, 1301-1307 (1995).
3. Bourcier T., Libby P., Arterioscler. Thromb. Vasc. Biol., 20, 556-562 (2000).
4. Laufs U., Marra D., Node L., Liao J. K., J. Biol. Chem., 274, 21926-21931 (1999).
5. Knapp A. C., Huang J., Starling G., Kiener P. A., Atherosclerosis, 152, 217-227 (2000).
6. Kureishi Y., Luo Z., Shiojima I., Bialik, A., Fulton D., Lefer D. J., Sessa W. C., Walsh K., Nat. Med., 6, 1004-1010 (2000).
7. Wassmann S., Laufs U., Baumer A. T., Muller K., Konkol C., Sauer H., Bohm M., Nickening, G., Mol. Pharmacol., 59, 646-654 (2000).
8. Takemoto M., Kitahara M., Yokote K., Asaumi S., Take A., Saito Y., Mori S. Br. J. Pharmacol., 133, 83-88 (2001).
9. Laufs U., La Feta V., Plutzky J., Liao J. K., Circulation, 97, 1129-1135 (1998).
10. Kajinami K., Mabushi H., Saito Y., Exp.Opin.Invest.Drugs, 9, 2653-2661 (2000).
11. Mosmann T., J. Immunol. Methods, 65, 55-63 (1983).
12. Kitajima I., Kawahara K., Nakajima T., Soejima Y., Matsuyama T., Maruyama I., Biochem.Biophys.Res. Com., 204, 244-251 (1994).
13. Kojima H., Sakurai K., Kikuchi K., Kawahara S., Kirino Y., Nagoshi H., Hirata Y., Nagano T., Chem. Pharm. Bull., 46, 373-375 (1998).
14. Nakatsubo N., Kojima H., Kikuchi K., Nagoshi H., Hirata Y., Maeda D., Imai Y., Irimura T., Nagano T., FEBS Lett., 427, 263-266 (1998).
15. Laufs U., La Fata V., Liao J. K., J. Biol. Chem., 272, 31725-31729 (1997).
16. Forstermann U., Boissel J. P., Kleinert H., FASEB J., 12, 773-790 (1998).
17. Geller D. A., Billiar T. R., Cancer Metastasis Rev., 17, 7-23 (1998).
18. Kroncke K. D., Feshel K., Kolbbachofen V., Clin. Exp. Immunol., 113, 147-156 (1998).
19. Wagner A. H., Schwabe O., Hecker M., Br. J. Pharmacol., 136, 143-149 (2002).
20. Huang K. C., Chen C. W., Chen J. C., Lin W.W., J. Biomed. Sci., 10, 396-405 (2003).
21. Garcia-Cardena G., Fan R., Shah V., Sorrentino R., Cirino G., Papapetropoulos A., Sessa W. C., Nature, 392, 821-824 (1998).
22. Feron O., Dessy C., Desager J. P., Balligand J. L., Circulation, 103, 113-118 (2001).